Kidney Cancer

Adding to Standard Treatment Increases the Number of Children Cured of Wilms Tumor

ASCO Annual Meeting
May 13, 2015

Two phase III Children’s Oncology Group studies found that using additional drugs with standard therapy lowered the chance that Wilms tumor with a specific genetic change returned after treatment. Wilms tumor is a rare type of cancer that begins in a child’s kidney. When it comes back after treatment, it is called a relapse or recurrence.

No Benefit Seen With Targeted Therapy After Surgery for Locally Advanced Kidney Cancer

Genitourinary Cancers Symposium
February 23, 2015

A recent study suggests that people with locally advanced kidney cancer should not take either sorafenib (Nexavar) or sunitinib (Sutent) after surgery. Sorafenib and sunitinib are two drugs that are widely used to treat kidney cancer that has spread to other parts of the body. They target the process of angiogenesis, blocking the growth of new blood vessels to the tumor. Because a tumor needs the nutrients delivered by blood vessels to grow and spread, the goal of anti-angiogenesis therapies is to “starve” the tumor.

Promising New Immunotherapy for Melanoma, Kidney Cancer, and Non-Small Cell Lung Cancer

ASCO Annual Meeting
June 2, 2012

A new immunotherapy (called BMS-936558) helped shrink melanoma, kidney cancer, and non-small cell lung cancer (NSCLC) in a recent early study. Immunotherapy is designed to boost the body's natural defenses to fight the cancer. It uses materials either made by the body or in a laboratory to bolster, target, or restore immune system function.

Subscribe to RSS - Kidney Cancer